Embla Medical (EMBLA) investor relations material

R&D organization and team

• R&D teams are distributed across a main center in Iceland and six global satellite sites, with over 200 professionals, two-thirds based in Iceland.

• The team is highly skilled and diverse, with 75% holding engineering degrees and 36% women, representing 25 nationalities.

• Average tenure is eight years, and the company has been ranked among the top 100 for sustainable growth by TIME Magazine.

• The company holds around 2,000 patents, 190 design patents, and 820 trademarks.

Innovation strategy and investment

• R&D investments totaled $190 million over the past five years, with a planned 50% increase from 2026 to 2030.

• About two-thirds of R&D spending targets innovative premium product development for chronic needs.

• R&D represents 7-8% of product sales and 5% of total sales including patient care.

Innovation model and pipeline

• New product development follows a structured stage-gate process from ideation to commercial launch, typically taking 1-6 years.

• The innovation pipeline is robust, with multiple programs in prosthetics, neuro orthotics, and bracing/supports.

• Recent flagship launches include Power Knee, Proprio Foot, Navii, Icon, and AeroFit Gen 3.

• Over 25% of sales now come from products launched in the last five years.